Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications BERKELEY,...
After Reevaluating its Near-term Capital Needs Given the Recent Changes in its Projected 2026 Revenue and Mayo Collaboration, the Company Determined that a $15 Million Offering is Not Required to Achieve...
With strong underlying market demand, European distributor and expert physician customer purchase orders are being received by the Company as its 2026 revenue guidance range increases to $1.5 million -...
Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new...
Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new...
BERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology...
Study conducted at US sites evaluates Lumee TM in peripheral artery disease (PAD) patients BERKELEY, Calif, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”)...
Research-use-only offerings are commercially available, enabling immediate product and service revenue generation Targets the global CRO market of $47.9 billion in 2025 and growing at 7% CAGR ...
Dr. Theodosios Bisdas is a renowned vascular surgeon and Head of Clinic of Vascular Surgery at the Athens Medical Center BERKELEY, Calif, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa”...
MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now...